The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
作者信息
Treon Steven P, Castillo Jorge J, Skarbnik Alan P, Soumerai Jacob D, Ghobrial Irene M, Guerrera Maria Luisa, Meid Kirsten, Yang Guang
机构信息
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.
Department of Medicine, Harvard Medical School, Boston, MA.
出版信息
Blood. 2020 May 21;135(21):1912-1915. doi: 10.1182/blood.2020006288.
Abstract
摘要
相似文献
1
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼可能对新冠病毒感染患者的肺损伤具有保护作用。
Blood. 2020 May 21;135(21):1912-1915. doi: 10.1182/blood.2020006288.
2
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.布鲁顿酪氨酸激酶抑制剂在慢性淋巴细胞白血病合并新型冠状病毒肺炎患者中的保护作用
Br J Haematol. 2020 Jul;190(2):e73-e76. doi: 10.1111/bjh.16863. Epub 2020 Jun 4.
3
Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.华氏巨球蛋白血症患者的依鲁替尼撤药症状。
Haematologica. 2018 Jul;103(7):e307-e310. doi: 10.3324/haematol.2017.186908. Epub 2018 Feb 22.
4
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.华氏巨球蛋白血症中的第一代和第二代布鲁顿酪氨酸激酶抑制剂
Hematol Oncol Clin North Am. 2018 Oct;32(5):853-864. doi: 10.1016/j.hoc.2018.05.012. Epub 2018 Jul 19.
5
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).在感染 COVID-19 的癌症患者中使用 BTK 抑制剂：“胜者将是那个能控制住混乱局面的人”（拿破仑·波拿巴）。
Clin Cancer Res. 2020 Jul 15;26(14):3514-3516. doi: 10.1158/1078-0432.CCR-20-1427. Epub 2020 Apr 28.
6
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.一项头对头的 III 期研究比较了zanubrutinib 与 ibrutinib 在华氏巨球蛋白血症患者中的疗效。
Future Oncol. 2018 Sep;14(22):2229-2237. doi: 10.2217/fon-2018-0163. Epub 2018 Jun 5.
7
CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.巴塞罗那医院诊所的慢性淋巴细胞白血病与新冠疫情：中期报告
Leukemia. 2020 Jul;34(7):1954-1956. doi: 10.1038/s41375-020-0870-5. Epub 2020 May 19.
8
Zanubrutinib for the treatment of Waldenström Macroglobulinemia.泽布替尼用于治疗华氏巨球蛋白血症。
Expert Rev Hematol. 2020 Dec;13(12):1303-1310. doi: 10.1080/17474086.2020.1851184. Epub 2020 Dec 9.
9
Ibrutinib in the management of Waldenstrom macroglobulinemia.伊布替尼用于治疗华氏巨球蛋白血症
J Oncol Pharm Pract. 2019 Mar;25(2):434-441. doi: 10.1177/1078155218786037. Epub 2018 Jul 12.
10
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.基于结构的虚拟筛选揭示伊布替尼和泽布替尼可能成为对抗 COVID-19 的潜在再利用药物。
Int J Mol Sci. 2021 Jun 30;22(13):7071. doi: 10.3390/ijms22137071.
引用本文的文献
1
Meta-analysis of mortality factors after COVID-19 infection in pediatric oncology patients.儿童肿瘤患者新冠病毒感染后死亡因素的荟萃分析
Front Oncol. 2025 Aug 6;15:1594617. doi: 10.3389/fonc.2025.1594617. eCollection 2025.
2
Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization.阿卡替尼联合最佳支持治疗与单纯最佳支持治疗对需要住院治疗的COVID-19患者的疗效和安全性。
Immunohorizons. 2025 May 30;9(7). doi: 10.1093/immhor/vlaf023.
3
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.一项关于BTK抑制剂泽布替尼在新冠病毒肺炎呼吸窘迫住院患者中的随机、安慰剂对照试验：免疫生物标志物及临床发现
Front Immunol. 2025 Jan 21;15:1369619. doi: 10.3389/fimmu.2024.1369619. eCollection 2024.
4
Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma.淋巴瘤患者中与新型冠状病毒肺炎相关的肺炎的预后危险因素
Front Oncol. 2025 Jan 6;14:1504809. doi: 10.3389/fonc.2024.1504809. eCollection 2024.
5
[Single-center study of COVID-19 in patients with chronic lymphocytic leukemia].慢性淋巴细胞白血病患者新冠病毒病的单中心研究
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):923-930. doi: 10.3760/cma.j.cn121090-20240621-00230.
6
The Immunomodulatory Mechanisms of BTK Inhibition in CLL and Beyond.布鲁顿酪氨酸激酶（BTK）抑制在慢性淋巴细胞白血病及其他疾病中的免疫调节机制
Cancers (Basel). 2024 Oct 23;16(21):3574. doi: 10.3390/cancers16213574.
7
Effect of Mixed Probiotics on Alleviating H1N1 Influenza Infection and Regulating Gut Microbiota.混合益生菌对减轻甲型H1N1流感感染及调节肠道微生物群的作用
Foods. 2024 Sep 27;13(19):3079. doi: 10.3390/foods13193079.
8
Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models.新型冠状病毒病的免疫生物学：来自动物模型的机制和治疗见解。
Zool Res. 2024 Jul 18;45(4):747-766. doi: 10.24272/j.issn.2095-8137.2024.062.
9
The impact of Bruton's tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia.布鲁顿酪氨酸激酶抑制剂治疗对中国慢性淋巴细胞白血病患者新冠病毒病结局的影响
Front Oncol. 2024 May 21;14:1396913. doi: 10.3389/fonc.2024.1396913. eCollection 2024.
10
Clinical Features and Prognostic Predictors in Patients with Renal Transplant Complicated by SARS-CoV-2 Infection, a Retrospective Single-Center Study.肾移植合并新型冠状病毒2感染患者的临床特征及预后预测因素：一项回顾性单中心研究
Infect Drug Resist. 2024 May 20;17:1999-2007. doi: 10.2147/IDR.S465805. eCollection 2024.
本文引用的文献
1
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.依鲁替尼预处理可减少细胞因子分泌，并降低慢性淋巴细胞白血病患者中奥滨尤妥珠单抗诱导的输注相关反应风险：来自iLLUMINATE研究的分析
Ann Hematol. 2021 Jul;100(7):1733-1742. doi: 10.1007/s00277-021-04536-6. Epub 2021 May 20.
2
Covid-19 in Critically Ill Patients in the Seattle Region - Case Series.西雅图地区危重症新冠患者-病例系列。
N Engl J Med. 2020 May 21;382(21):2012-2022. doi: 10.1056/NEJMoa2004500. Epub 2020 Mar 30.
3
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
4
[A pathological report of three COVID-19 cases by minimal invasive autopsies].[三例新冠病毒病病例微创尸检病理报告]
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417. doi: 10.3760/cma.j.cn112151-20200312-00193.
5
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.中国武汉 2019 年冠状病毒病肺炎患者急性呼吸窘迫综合征和死亡的相关危险因素。
JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.
6
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
7
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
8
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
9
Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury.抑制布鲁顿酪氨酸激酶可挽救小鼠免于致死性流感诱导的急性肺损伤。
Am J Physiol Lung Cell Mol Physiol. 2018 Jul 1;315(1):L52-L58. doi: 10.1152/ajplung.00047.2018. Epub 2018 Mar 8.
10
BTK drives ibrutinib resistance via ERK1/2 and protects BTK MYD88-mutated cells by a paracrine mechanism.BTK 通过 ERK1/2 驱动伊布替尼耐药，并通过旁分泌机制保护 BTK MYD88 突变细胞。
Blood. 2018 May 3;131(18):2047-2059. doi: 10.1182/blood-2017-10-811752. Epub 2018 Mar 1.
Zotero 插件